Main info

Identifier:

HO26 NHL

Sponsor:

HOVON

Included patients:

513

Active sites:

0

(of 59)

59 sites are pending

Title:

Intensified CHOP of 12-Weeks Duration plus G-CSF as compared with Standard CHOP of 24-Weeks Duration for Patients with Intermediate-Prognosis Non-Hodgkin's Lymphoma.

Timeline

Flow

Details

Phase:

Prospective randomized Phase III study

Monitoring Type:

Objectives:

Eligibility

Inclusion Criteria:

• Previously untreated patients with a primary NHL of intermediate- or high-grade malignancy according to the Working Formulation. The lymphoblastic lymphomas are excluded.
• Belonging to the intermediate-risk group.

Exclusion Criteria:

• Patients with NHL of intermediate- or high-grade malignancy but with: - ages < 15 years and > 65 years. - belonging to the low- or high-risk group.
• Patients with prior malignancies, except stage I cervix carcinoma and basocellular carcinoma.
• Patients with severe cardiac, pulmonary, neurologic or metabolic disease.
• Inadequate liver or renal function.
• HIV positivity.
• Inability to give informed consent.
• Involvement of the central nervous system.

Participating Sites

= Active hospitals

= Inactive hospitals